نتایج جستجو برای: tb vaccine

تعداد نتایج: 133682  

Journal: :The Ceylon medical journal 2006
K R C P Kekulawala B J C Perera J Senevirathna C S Perera

Disseminated tuberculosis is rare in infants. The more common presentations of tuberculosis (TB) in infancy include pulmonary and meningeal involvement. Disseminated TB following BCG vaccination is even rarer. The possible reasons for dissemination following BCG are faulty techniques of intra-dermal administration and use of excess doses of the vaccine. Dissemination following BCG also occurs i...

Journal: :Cell host & microbe 2017
Albanus O Moguche Munyaradzi Musvosvi Adam Penn-Nicholson Courtney R Plumlee Helen Mearns Hennie Geldenhuys Erica Smit Deborah Abrahams Virginie Rozot One Dintwe Søren T Hoff Ingrid Kromann Morten Ruhwald Peter Bang Ryan P Larson Shahin Shafiani Shuyi Ma David R Sherman Alessandro Sette Cecilia S Lindestam Arlehamn Denise M McKinney Holden Maecker Willem A Hanekom Mark Hatherill Peter Andersen Thomas J Scriba Kevin B Urdahl

CD4 T cells are critical for protective immunity against Mycobacterium tuberculosis (Mtb), the cause of tuberculosis (TB). Yet to date, TB vaccine candidates that boost antigen-specific CD4 T cells have conferred little or no protection. Here we examined CD4 T cell responses to two leading TB vaccine antigens, ESAT-6 and Ag85B, in Mtb-infected mice and in vaccinated humans with and without unde...

2011
Kristin L. Griffiths Ansar A. Pathan Angela M. Minassian Clare R. Sander Natalie E. R. Beveridge Adrian V. S. Hill Helen A. Fletcher Helen McShane

Vaccination with Bacille Calmette-Guérin (BCG) has traditionally been used for protection against disease caused by the bacterium Mycobacterium tuberculosis (M.tb). The efficacy of BCG, especially against pulmonary tuberculosis (TB) is variable. The best protection is conferred in temperate climates and there is close to zero protection in many tropical areas with a high prevalence of both tube...

2014
Amaya Leunda Aline Baldo Martine Goossens Kris Huygen Philippe Herman Marta Romano

Novel efficient vaccines are needed to control tuberculosis (TB), a major cause of morbidity and mortality worldwide. Several TB vaccine candidates are currently in clinical and preclinical development. They fall into two categories, the one of candidates designed as a replacement of the Bacille Calmette Guérin (BCG) to be administered to infants and the one of sub-unit vaccines designed as boo...

Journal: :Infection and immunity 2003
Jeffrey M Chen David C Alexander Marcel A Behr Jun Liu

Mycobacterium bovis BCG is the only accepted vaccine for the prevention of tuberculosis (TB) in humans. BCG is a live vaccine, and induction of immunity to TB requires productive infection of the host by BCG. However, BCG is not a satisfactory vaccine, because it fails to protect against pulmonary TB in adults. In this study, we found that BCG strains cannot utilize many naturally occurring ami...

2012
Rolf Billeskov Tara T. Elvang Peter L. Andersen Jes Dietrich

BACKGROUND The current vaccine against tuberculosis (TB), BCG, has failed to control TB worldwide and the protective efficacy is moreover limited to 10-15 years. A vaccine that could efficiently boost a BCG-induced immune response and thus prolong protective immunity would therefore have a significant impact on the global TB-burden. METHODS/FINDINGS In the present study we show that the fusio...

2013
Jayne S. Sutherland Maeve K. Lalor Gillian F. Black Lyn R. Ambrose Andre G. Loxton Novel N. Chegou Desta Kassa Adane Mihret Rawleigh Howe Harriet Mayanja-Kizza Marie P. Gomez Simon Donkor Kees Franken Willem Hanekom Michel R. Klein Shreemanta K. Parida W. Henry Boom Bonnie A. Thiel Amelia C. Crampin Martin Ota Gerhard Walzl Tom H. M. Ottenhoff Hazel M. Dockrell Stefan H. E. Kaufmann

BACKGROUND Tuberculosis (TB) remains a global health threat with 9 million new cases and 1.4 million deaths per year. In order to develop a protective vaccine, we need to define the antigens expressed by Mycobacterium tuberculosis (Mtb), which are relevant to protective immunity in high-endemic areas. METHODS We analysed responses to 23 Mtb antigens in a total of 1247 subjects with different ...

Journal: :ALTEX 2014
Marilena P Etna Elena Giacomini Martina Severa Manuela Pardini Nacho Aguilo Carlos Martin Eliana M Coccia

Among the tuberculosis (TB) vaccine candidates, SO2 is the prototype of the first live-attenuated vaccine that recently entered into clinical trials. To investigate the capacity of SO2 to stimulate an appropriate immune response in vitro within a human immunological context, a comparative analysis of the effects promoted by SO2, the current Bacille Calmette-Guerin (BCG) vaccine and Mycobacteriu...

Journal: :Molecular therapy : the journal of the American Society of Gene Therapy 2016
Lu Zhang Huan-Wei Ru Fu-Zeng Chen Chun-Yan Jin Rui-Feng Sun Xiao-Yong Fan Ming Guo Jun-Tao Mai Wen-Xi Xu Qing-Xia Lin Jun Liu

Bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, is the only vaccine available for tuberculosis (TB) control. However, BCG is not an ideal vaccine and has two major limitations: BCG exhibits highly variable effectiveness against the development of TB both in pediatric and adult populations and can cause disseminated BCG disease in immunocompromised individuals. BCG co...

2018
Anneliese S Ashhurst Thaigarajan Parumasivam John Gar Yan Chan Leon C W Lin Manuela Flórido Nicholas P West Hak-Kim Chan Warwick J Britton

Tuberculosis places a staggering burden on human health globally. The new World Health Organisation End-TB Strategy has highlighted the urgent need for more effective TB vaccines to improve control of the disease. Protein-based subunit vaccines offer potential as safe and effective generators of protective immunity, and the use of particulate vaccine formulation and delivery by the pulmonary ro...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید